
Future Journal of Pharmaceutical Sciences, Год журнала: 2025, Номер 11(1)
Опубликована: Фев. 5, 2025
Abstract Background Breast carcinoma (BC) and lung (LC) have the highest incidence mortality rates worldwide. In prior work, studied sample hub targets contributing to anticancer potential against BC LC were identified through network pharmacology. present web servers UALCAN, GEPIA2, KM plotter used explore genomic proteomic expression of these targets, along with their prognosis in LC. Results Differential SRC, MAPK3, PTPN11, JAK2, ESR1, HAP900A1 for EGFR, MAPK3 LC, showed good prognostic potentials. Collectively, ESR1 overlapped differential expressed involved significantly both carcinoma. Conclusion These differentially may be taken into account future treatments due strong potential.
Язык: Английский